Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:2071-2077
Published online before print July 10, 2008, doi: 10.1161/ATVBAHA.108.168690
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
28/11/2071    most recent
ATVBAHA.108.168690v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murphy, A. J.
Right arrow Articles by Chin-Dusting, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murphy, A. J.
Right arrow Articles by Chin-Dusting, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*12-O-TETRADECANOYLPHORBOL-13-ACETATE
*CHOLESTEROL
Related Collections
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:2071.)
© 2008 American Heart Association, Inc.


Cell Biology/Signaling

High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response

Andrew J. Murphy; Kevin J. Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A. Stirzaker; Sally P.A. McCormick; Alan T. Remaley; Dmitri Sviridov; Jaye Chin-Dusting

From the Laboratories of Vascular Pharmacology (A.J.M., K.J.W., J.C.D.) and Lipoproteins and Atherosclerosis (A.H., N.M., D.S.), Baker Heart Research Institute, Melbourne, Victoria, Australia; Molecular Medicine (R.A.S.), The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia; the Department of Biochemistry (S.P.A.M.), University of Otago, Dunedin, Otago, New Zealand; and the Lipoprotein Metabolism Section (A.T.R.), National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Md.

Correspondence to Jaye Chin-Dusting, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Victoria 8008 Australia. E-mail jaye.chin-dusting{at}baker.edu.au

Objective— Whereas the anti–inflammatory effects of high-density lipoprotein (HDL) on endothelial cells are well described, such effects on monocytes are less studied.

Methods and Results— Human monocytes were isolated from whole blood followed by assessment of CD11b activation/expression and cell adhesion under shear-flow. HDL caused a dose-dependent reduction in the activation of CD11b induced by PMA or receptor-dependent agonists. The constituent of HDL responsible for the antiinflammatory effects on CD11b activation was found to be apolipoprotein A-I (apoA-I). Cyclodextrin, but not cyclodextrin/cholesterol complex, also inhibited PMA-induced CD11b activation implicating cholesterol efflux as the main mechanism. This was further confirmed with the demonstration that cholesterol content of lipid rafts diminished after treatment with the cholesterol acceptors. Blocking ABCA1 with an anti-ABCA1 antibody abolished the effect of apoA-I. Furthermore, monocytes derived from a Tangier disease patient definitively confirmed the requirement of ABCA1 in apoA-I–mediated CD11b inhibition. The antiinflammatory effects of apoA-I were also observed in functional models including cell adhesion to an endothelial cell monolayer, monocytic spreading under shear flow, and transmigration.

Conclusions— HDL and apoA-I exhibit an antiinflammatory effect on human monocytes by inhibiting activation of CD11b. ApoA-I acts through ABCA1, whereas HDL may act through several receptors.

High-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I) exhibit a potent antiinflammatory effect on human monocytes, inhibiting expression of the adhesion molecule CD11b, an effect mediated through cholesterol efflux. The effect of apoA-I was dependent on ABCA1, whereas HDL may act through multiple receptors.


Key Words: apolipoprotein A-I • CD11b • monocyte • ABCA1 • Tangier


Related Article:

Antiinflammatory Actions of HDL: A New Insight
Kerry-Anne Rye and Philip J. Barter
Arterioscler Thromb Vasc Biol 2008 28: 1890-1891. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Tang, Y. Liu, P. S. Kessler, A. M. Vaughan, and J. F. Oram
The Macrophage Cholesterol Exporter ABCA1 Functions as an Anti-inflammatory Receptor
J. Biol. Chem., November 20, 2009; 284(47): 32336 - 32343.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Sattler and B. Levkau
Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection
Cardiovasc Res, May 1, 2009; 82(2): 201 - 211.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K.-A. Rye and P. J. Barter
Antiinflammatory Actions of HDL: A New Insight
Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1890 - 1891.
[Full Text] [PDF]